[go: up one dir, main page]

WO2009035738A3 - Utilisation d'une analyse elispot de cellules sécrétrices d'anticorps pour évaluer les réponses des anticorps suite à leur exposition à un antigène - Google Patents

Utilisation d'une analyse elispot de cellules sécrétrices d'anticorps pour évaluer les réponses des anticorps suite à leur exposition à un antigène Download PDF

Info

Publication number
WO2009035738A3
WO2009035738A3 PCT/US2008/067142 US2008067142W WO2009035738A3 WO 2009035738 A3 WO2009035738 A3 WO 2009035738A3 US 2008067142 W US2008067142 W US 2008067142W WO 2009035738 A3 WO2009035738 A3 WO 2009035738A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
antigen exposure
secreting cell
following antigen
responses following
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/067142
Other languages
English (en)
Other versions
WO2009035738A2 (fr
Inventor
Frances Eun-Hyung Lee
Ignacio Sanz
Jessica Halliley
Ann R Falsey
Edward Walsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Priority to US12/663,343 priority Critical patent/US20100221755A1/en
Publication of WO2009035738A2 publication Critical patent/WO2009035738A2/fr
Publication of WO2009035738A3 publication Critical patent/WO2009035738A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention porte sur des procédés et des trousses permettant la détection précoce d'une exposition à un antigène, fondée sur la présence ou l'absence d'anticorps spécifiques d'antigène.
PCT/US2008/067142 2007-06-15 2008-06-16 Utilisation d'une analyse elispot de cellules sécrétrices d'anticorps pour évaluer les réponses des anticorps suite à leur exposition à un antigène Ceased WO2009035738A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/663,343 US20100221755A1 (en) 2007-06-15 2008-06-16 Use of antibody secreting cell elispot to assess antibody responses following antigen exposure

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94448407P 2007-06-15 2007-06-15
US60/944,484 2007-06-15

Publications (2)

Publication Number Publication Date
WO2009035738A2 WO2009035738A2 (fr) 2009-03-19
WO2009035738A3 true WO2009035738A3 (fr) 2009-05-14

Family

ID=40452765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/067142 Ceased WO2009035738A2 (fr) 2007-06-15 2008-06-16 Utilisation d'une analyse elispot de cellules sécrétrices d'anticorps pour évaluer les réponses des anticorps suite à leur exposition à un antigène

Country Status (2)

Country Link
US (1) US20100221755A1 (fr)
WO (1) WO2009035738A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2217250A4 (fr) 2007-11-09 2011-01-05 California Inst Of Techn Composés immunorégulateurs et compositions et procédés apparentés
US20110229914A1 (en) * 2009-10-21 2011-09-22 Frances Eun-Hyung Lee Use of Antibody Secreting Cell Elispot To Assess Antibody Responses Following Antigen Exposure
ES2694100T3 (es) 2010-04-07 2018-12-18 California Institute Of Technology Vehículo para distribuir un compuesto en una membrana mucosa y composiciones, procedimientos y sistemas relacionados
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
GB201212550D0 (en) * 2012-07-13 2012-08-29 Novartis Ag B cell assay
EP3502698A1 (fr) * 2014-05-05 2019-06-26 MicroBPlex, Inc. Milieux préparés avec des anticorps nouvellement synthétisés et leurs utilisations
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
CA2997211A1 (fr) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Compositions de psa lipides et procedes associes
EP3484441A4 (fr) 2016-07-15 2020-03-18 President and Fellows of Harvard College Compositions de glycolipide et procédés d'utilisation
CN110806476B (zh) * 2019-11-15 2021-10-08 中国农业科学院油料作物研究所 检测二乙酰镳草镰刀菌烯醇污染的免疫层析试纸条、制备方法及其应用
KR20230141851A (ko) * 2021-02-05 2023-10-10 암젠 인크 농축 하이브리도마 생성
WO2025062323A1 (fr) * 2023-09-22 2025-03-27 Elleon Biotech Limited Dosage immunologique lié à une enzyme avec milieu limitant la vitesse de diffusion

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050014205A1 (en) * 2002-11-08 2005-01-20 Rothel James Stuart Diagnostic assay for measuring a cell mediated immune response

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0438457A1 (fr) * 1988-10-14 1991-07-31 Syntello Ab Procede de detection simultanee de differents types d'anticorps et/ou d'antigenes produits par des cellules individuelles
AU2007265628B2 (en) * 2006-06-23 2012-12-06 Revvity Health Sciences, Inc. Methods and devices for microfluidic point-of-care immunoassays

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050014205A1 (en) * 2002-11-08 2005-01-20 Rothel James Stuart Diagnostic assay for measuring a cell mediated immune response

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CROTTY ET AL.: "Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system.", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 286, 2004, pages 111 - 122 *
HUANG ET AL.: "The Effect of Anti-CD40 Ligand Antibody on B Cells in Human Systemic Lupus Erythematosus.", ARTHRITIS & RHEUMATISM, vol. 46, no. 6, June 2002 (2002-06-01), pages 1554 - 1562 *
KANTELE ET AL.: "Peripheral blood antibody-secreting cells in the evaluation of the immune response to an oral vaccine.", JOURNAL OF BIOTECHNOLOGY, vol. 44, 1996, pages 217 - 224 *

Also Published As

Publication number Publication date
WO2009035738A2 (fr) 2009-03-19
US20100221755A1 (en) 2010-09-02

Similar Documents

Publication Publication Date Title
WO2009035738A3 (fr) Utilisation d'une analyse elispot de cellules sécrétrices d'anticorps pour évaluer les réponses des anticorps suite à leur exposition à un antigène
TWI800854B (zh) 全人源的抗ｂ細胞成熟抗原（ｂｃｍａ）單鏈抗體及其應用
LTC2376535I2 (lt) Anti-PD-L1 antikūnai ir jų panaudojimas T ląstelių funkcijos pagerinimui
EP4031150A4 (fr) Cellules t de récepteurs antigéniques chimériques (car) ciblées cd70 et leurs utilisations
BR112013010213A2 (pt) anticorpos que unem ligantes solúveis de receptores de célula t
CR20120312A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
WO2008073895A3 (fr) Procédés et dispositifs d'analyse de la salive
AU2018338418A1 (en) Anti-HLA-A2 antibodies and methods of using the same
IL202322A0 (en) Detection of antigens carried by erythrocytes and of anti-erythrocyte antibodies
NZ598194A (en) Anti-cmet antibody and its use for the detection and the diagnosis of cancer
BRPI0812488A2 (pt) Anticorpos anti-cd44 humanizados e quiméricos que mediam citotoxidade de célula de câncer, usos dos mesmos, ensaios de ligação, métodos, composições e kit de ensaio
EP2566890A4 (fr) Anticorps anti-pai-1 et leurs procédés d'utilisation
MX344935B (es) Analisis para detectar anticuerpos especificos a anticuerpos anti-ige terapeuticos y su uso en anafilaxis.
WO2007100908A3 (fr) Vecteurs anédoviraux chimériques
WO2014066271A8 (fr) Cellules de lignage non b capables de produire des anticorps
NO20076662L (no) Deteksjon av et malantigen uavhengig av tilstedevaerelse eller fravaer av et korresponderende terapeutisk antistoff
BR112013013573A2 (pt) método para produzir anticorpos específicos para um antígeno de interesse, célula b isolada ou recombinante, população de anticorpo, e, anticorpo
NZ609824A (en) Immunochromatography devices, methods and kits
MX2012003825A (es) Anticuerpos anti igg reactivos no cruzados.
WO2008117195A3 (fr) Utilisation de billes micro-porteuses pour la détection et/ou l'isolement de cellules par cytométrie en flux et/ou diélectrophorèse
BR112012033163A2 (pt) ''anticorpos monoclonais, linhagens celulares, usos de um anticorpo, kit, métodos para detectar um anticorpo, composição de anticorpo e uso de uma composição de anticorpo''
DE602007012836D1 (de) Cd86- und cd80-rezeptorkonkurrenztests
BRPI0816689A2 (pt) antígenos mutantes gas57 e anticorpos gas57
NO20083609L (no) Fremgangsmater og sammensetninger for malrettet-RELT
WO2010056889A3 (fr) Utilisation d'un anticorps et d'un cristal à base de terre rare

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08830532

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12663343

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 08830532

Country of ref document: EP

Kind code of ref document: A2